N/A
N=763
Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel
Spondyloarthrosis
Bottom Line
View on ClinicalTrials.gov: NCT04507776 ↗Enrolled (actual)
763
Serious AEs
—
Results posted
Oct 2021
Primary outcome: Primary: Percentage of Participants With 7 Years Adherence to Etanercept — 60.6 Percentage of participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Etanercept (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Oct 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With 7 Years Adherence to Etanercept |
60.6 | — |
Summary
This study is to evaluate local data in Iraqi patients with Spondyloarthropathies on Enbrel treatment with regards to efficacy and adherence using data from the Baghdad Teaching Hospital (Rheumatology Center)
Eligibility Criteria
Inclusion Criteria
- Diagnosed SpA patients
- 18 years of age and older.
- Did not receive previous other biological treatments.
- Patients have at least 1 year on Enbrel.
Exclusion Criteria
- Had previously used another biological treatments.
- Use of etanercept for less than 1 year duration.
Data sourced from ClinicalTrials.gov (NCT04507776). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.